Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma.

ABSTRACT: The identification of BRAF V600 mutation in multiple cancers beyond melanoma and the development of combined BRAF and MEK targeting agents have altered the landscape of tissue-agnostic precision oncology therapies with an impact on survival outcomes. Despite initial efficacy, resistance emerges, and it is pertinent to identify putative resistance mechanisms. We report a case of recurrent glioblastoma (GBM) harboring BRAF V600E alteration who initially responded to combined BRAF + MEK inhibition and subsequently developed treatment resistance by histological transformation to gliosarcoma and acquisition of oncogenic KRAS ^G12D and an NF1 ^L1083R mutation. This documented case represents an initial evidence of a developing phenomenon in cancer research as it provides the

SUBMITTER: Nelson BE 

PROVIDER: S-EPMC10212928 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature